After numerous failures of the therapeutic strategies acting against Aβ, and the different works that strongly associated tau alterations to AD, many researchers focused their attention also on therapeutic strategies to target tau (Panza et al., 2016) by acting on the block or prevention of tau phosphorylation, through the activity of specific kinases or phosphatases, as well as on either inhibiting its aggregation or promoting its clearance (Iqbal et al., 2014; Anand and Sabbagh, 2015; Pedersen and Sigurdsson, 2015). The gene discussed is MAPT; the disease is Alzheimer disease.